Join our daily newsletter At The Bell to receive exclusive market insights
- Biotech company Radiopharm Theranostics (RAD) signs a letter of intent with global oncology provider GenesisCare to start is first trial in Australia
- The company is developing a platform of radiopharmaceutical products for both diagnostic and therapeutic uses
- The phase one trial will involve Radiopharm’s proprietary nanobody from its Nano-mAbs platform which targets the PDL1 expression in non-small cell lung cancer
- According to RAD, this is an area of high unmet need and there is potential for the treatment to be the “first in class” radiopharmaceutical therapy targeting PDL1
- On market close, Radiopharm is down 7.41 per cent and trading at 25 cents per share.
Radiopharm Theranostics (RAD) has signed a letter of intent with global oncology provider GenesisCare to start is first trial in Australia.
The company is developing a platform of radiopharmaceutical products for both diagnostic and therapeutic uses.
The phase one trial will involve Radiopharm’s proprietary nanobody from its Nano-mAbs
platform which targets the PDL1 expression in non-small cell lung cancer, the most common type of lung cancer.
Notably, according to RAD, this is an area of high unmet need and there is potential for the treatment to be the “first in class” radiopharmaceutical therapy targeting PDL1.
GenesisCare is a leading provider of integrated oncology care around the globe.
“We are proud to have entered an LOI with GenesisCare, Australia’s largest provider of integrated cancer care, to support a trial for our innovative radiopharmaceutical therapy targeting non-small cell lung cancer, pending ethics approval from Australian authorities,” Radiopharm CEO & Managing Director Riccardo Canevari said.
“This is currently an area of high unmet need, and we are hopeful of bringing a first in class treatment to the market that will greatly improve patient outcomes. The phase one trial is an important milestone on the path to making this a reality.”
Work has already commenced under the letter of intent and the corresponding services agreement is currently being negotiated.
On market close, Radiopharm was down 7.41 per cent and trading at 25 cents per share.
